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Divergent effects of adrenaline in human induced pluripotent stem
cell-derived cardiomyocytes obtained from hypertrophic
cardiomyopathy
Chandra Prajapati1, Marisa Ojala1 and Katriina Aalto-Setälä1,2,3,*
ABSTRACT
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac
disease that affects the heart muscle with diverse clinical outcomes.
HCM can cause sudden cardiac death (SCD) during or immediately
after mild to rigorous physical activity in young patients. However, the
mechanism causing SCD as a result of exercise remains unknown,
but exercise-induced ventricular arrhythmias are thought to be
responsible for this fatal consequence. To understand the disease
mechanism behind HCM in a better way, we generated patient-
specific induced pluripotent stem cell-derived cardiomyocytes
(hiPSC-CMs) from HCM patients carrying either the MYBPC3-
Gln1061X or TPM1-Asp175Asn mutation. We extensively
investigated the effects of low to high concentrations of adrenaline
on action potential characteristics, and the occurrence of arrhythmias
in the presence of various concentrations of adrenaline and in wash-
out condition. We classified and quantified different types of
arrhythmias observed in hiPSC-CMs, and found that the occurrence
of arrhythmias was dependent on concentrations of adrenaline and
positions of mutations in genes causing HCM. In addition, we
observed ventricular tachycardia types of arrhythmias in hiPSC-
CMs carrying the TPM1-Asp175Asn mutation. We additionally
examined the antiarrhythmic potency of bisoprolol in HCM-specific
hiPSC-CMs. However, bisoprolol could not reduce the occurrence of
arrhythmias during administration or during the wash-out condition of
adrenaline in HCM-specific hiPSC-CMs. Our study demonstrates
hiPSC-CMs as a promising tool for studying HCM. The experimental
design used in this study could be suitable and beneficial for studying
other components and drugs related to cardiac disease in general.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac
disease found worldwide, irrespective of age, sex or ethnic group.
HCM is characterized by unexplained left ventricular hypertrophy,
mostly in the interventricular septum, but it can also affect other
areas of the left ventricle (Maron and Maron, 2013). Histologically,
HCM is characterized by myocardial disarray and fibrosis. More
than 1400 distinct mutations in >11 genes encoding proteins of
cardiac sarcomeres have been associated with HCM, most of which
are unique to individual families (Maron and Maron, 2013). Two
founder mutations in alpha-tropomyosin (TPM1-Asp175Asn, 6.5%)
and in myosin-binding protein C (MYBPC3-Gln1061X, 11.4%)
genes together account for ∼18% of HCM in Finland (Jääskeläinen
et al., 2013). HCM patients often have ventricular arrhythmias such
as non-sustained ventricular tachycardia (NSVT) (Monserrat et al.,
2003) and supraventricular arrhythmias such as atrial fibrillation
(Adabag et al., 2005). In worst cases, the first manifestation of HCM
could be sudden cardiac death (SCD), usually caused by ventricular
tachyarrhythmias (Maron and Maron, 2014). It is known that HCM
undergoes remodeling of different ion channels, but how these
adaptations endorse repolarization abnormalities and engender
lethal arrhythmias is not yet understood (Tomaselli and Marbán,
1999). The reduced number of β-receptor binding sites (Choudhury
et al., 1996) and the blunt β-adrenergic signaling pathway have been
identified, but interestingly the plasma catecholamine concentration
remains unaltered in HCM patients (Schumacher et al., 1995). An
earlier study showed that plasma adrenaline does not significantly
differ in resting conditions and during exercise between control and
HCM groups (Omodani et al., 1998). However, SCD occurs during
or immediately after moderate to severe physical activity in HCM
patients (van Rijsingen et al., 2011). Although exercise-induced
arrhythmias have been associated with an increased risk of SCD, the
precise mechanism for SCD has not yet been identified (Gimeno
et al., 2009). HCM patients are recommended not to participate in
competitive exercise because of impaired hemodynamics and
tolerance during exercise (Elliott et al., 2014). Clinically, study of
exercise-induced arrhythmias in HCM is challenging. In an early
study, eight of 15 HCM patients stopped exercise because of
shortness of breath or leg fatigue (Omodani et al., 1998). Currently,
there is no disease-specific pharmacological treatment available
for HCM patients (Spoladore et al., 2012); an implantable
cardioverter-defibrillator (ICD) is the only effective available tool
for prevention of SCD (Maron et al., 2000). Therefore, a better
understanding of the triggers for lethal ventricular arrhythmias in
HCM is necessary.
Prior studies of cardiovascular diseases in animal models have
some fundamental problems, such as differences in cardiac
physiology, drug responses (O’Hara and Rudy, 2012), and the
expression of contractile proteins. Therefore, it is complicated to
extrapolate the physiological and pharmacological results from
animals to humans (Jung and Bernstein, 2014). In addition, cardiac
biopsies from humans are limited and typically obtained from the
end stages of cardiac diseases (Barajas-Martínez et al., 2013);
hence, it is not possible to understand the mechanisms leading to
cardiac diseases. These impedances of in vitro cardiac disease
modeling are mostly overcome by the groundbreaking discovery ofReceived 2 November 2017; Accepted 22 December 2017
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reprogramming adult somatic cells into induced pluripotent stem
cells (iPSCs) (Takahashi et al., 2007), which can be differentiated
into any cell type of the human organism, such as human iPSC-
derived cardiomyocytes (hiPSC-CMs) (Kujala et al., 2012; Ojala
et al., 2016). In addition, hiPSC-CMs offer a robust platform for
in vitro studies of genetic cardiac disorders. We have previously
shown that HCM-specific hiPSC-CMs carrying TPM1-Asp175Asn
or MYBPC3-Gln1061X mutations showed differences in cell
morphology, calcium handling properties and electrophysiological
properties, not only from the control but also between these two
mutations (Ojala et al., 2016). This study is a follow-up study with
comprehensive analysis of the effects of different concentrations of
adrenaline on action potential (AP) characteristics and the
occurrence of arrhythmias in HCM-specific hiPSC-CMs during
and immediately after adrenaline administration. We concentrated
on the use of adrenaline because it is a natural physiological agent
and plasma adrenaline increases during exercise (Omodani et al.,
1998; Warren et al., 1984). Furthermore, we evaluated the beat rate
and repolarization variabilities of these hiPSC-CMs to identify the
potential link with the occurrence of arrhythmias. Finally, we also
examined the efficacy of the β-blocker bisoprolol in subsiding
arrhythmias in HCM-specific hiPSC-CMs.
RESULTS
Electrophysiological categorization of hiPSC-CMs
In this study, hiPSC-CMs were categorized as ventricular-like
[action potential duration (APD) at 90%/50% repolarization
(APD90/APD50)<1.3] and atrial-like (APD90/APD50>1.35)
mainly based on the triangularity of the AP profile.
Atrial-like hiPSC-CMs
The minority (∼20%) of the hiPSC-CMs exhibited the atrial type of
AP profile in hiPSC-CMs derived from control hiPSCs (WT-CMs),
hiPSC-CMs carrying the TPM1-Asp175Asn mutation (HCMT-
CMs) and hiPSC-CMs carrying the MYBPC3-Gln1061X mutation
(HCMM-CMs). Only baseline characteristics were evaluated from
atrial-like hiPSC-CMs and none of the AP characteristics of atrial
cells were significantly different among WT-CMs (n=21), HCMT-
CMs (n=30) and HCMM-CMs (n=34) (Table S1).
Ventricular-like hiPSC-CMs
The majority (∼80%) of the hiPSC-CMs exhibited the ventricular-
like hiPSC-CMs in all groups. The baseline characteristics of
ventricular-like hiPSC-CMs have been presented in our previous
study (Ojala et al., 2016). In this study, adrenaline and bisoprolol
testing was performed only in ventricular-like hiPSC-CMs.
Voltage-gated ionic currents in hiPSC-CMs
Previous studies have shown that either gain or loss of function of
different voltage-gated ion channels alter the AP profile, and thus
facilitate the occurrence of arrhythmias in HCM (Coppini et al.,
2013; Gomez et al., 1997). To understand the remodeling of ion
channels in HCM, calcium current (ICa), transient outward
potassium current (Ito) and inward rectifier potassium current
(IK1) were measured in hiPSC-CMs (Fig. 1). The ICa current
densities were significantly higher in HCMT-CMs (n=23) and
HCMM-CMs (n=14) than in WT-CMs (n=15) (P<0.05, WT versus
HCMT, from −10 mV to 70 mV, and WT versus HCMM, from
10 mV to 60 mV; one-way ANOVA, post hoc Tukey test).
However, no statistical differences in ICa current densities were
found between HCMT-CMs and HCMM-CMs at any potential
(Fig. 1A). By contrast, Ito current densities were significantly lower
in both HCMT-CMs (n=22) and HCMM-CMs (n=23) compared to
WT-CMs (n=16) from 20 mV to 70 mV (P<0.05, one-way
ANOVA, post hoc Tukey test; Fig. 1B). No significant differences
in Ito current densities were found between HCMT-CMs and
Fig. 1. Voltage-gated ionic currents in ventricle-like WT-CMs, HCMT-CMs and HCMM-CMs. (A) Current-voltage (I-V) relationship of L-type calcium current
(ICa) (above) and voltage clamp protocol used (below). P<0.05 from −10 mV to 60 mV (WT-CMs versus HCMT-CMs, one-way ANOVA, post hoc Tukey test).
P<0.05 from 10 mV to 60 mV (WT-CMs versus HCMM-CMs, one-way ANOVA, post hoc Tukey test). (B) I-V relationship of transient outward potassium current
(Ito) (above) and voltage clamp protocol used (below). P<0.05 from 30 mV to 70 mV (WT-CMs versus HCMT-CMs and WT-CMs versus HCMM-CMs; one-way
ANOVA, post hoc Tukey test). (C) I-V relationship of inward rectifier outward current (IK1) (above) and voltage clamp protocol used (below) (ns at all test potentials,
WT-CMs versus HCMT-CMs and WT-CMs versus HCMM-CMs; one-way ANOVA, post hoc Tukey test). Data are mean±s.e.m. Values inside parentheses
represent the number of CMs used.
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HCMM-CMs at any potential. The IK1 current densities were not
significantly different at all potentials tested among groups
[nonsignificant (ns), WT-CMs, n=12; HCMT-CMs, n=19;
HCMM-CMs, n=21; one-way ANOVA, post hoc Tukey test;
Fig. 1C].
hiPSC-CMs exhibit various types of arrhythmias
Life-threatening arrhythmias and exercise-induced arrhythmias
primarily commence in the ventricle (Monserrat et al., 2003;
Gimeno et al., 2009). Thus, we especially focused on ventricular-
like hiPSC-CMs to understand these abnormalities. Patch-clamp
recordings of self-beating hiPSC-CMs demonstrated various types
of arrhythmias (Fig. 2; Fig. S1). Therefore, we categorized and
quantified these arrhythmias separately. The arrhythmias were
present either exclusively or in the presence of another type of
arrhythmia. The most common type of arrhythmia recorded from
hiPSC-CMs was delayed afterdepolarization (DAD). DAD was
defined as the presence of low-amplitude abnormal depolarization
after successive APs that can cause cessation of next spontaneous
APs (Fig. 2Aa; Fig. S1A). Both HCMT-CMs (52%, 136/263) and
HCMM-CMs (61%, 96/158) exhibited higher occurrence of DADs
compared to WT-CMs (23%, 23/102) at baseline (Fig. 2Ad). DADs
were also recorded from the atrial hiPSC-CMs (Fig. S2A) in
WT-CMs (5%, 1/21), HCMT-CMs (43%, 13/30) and HCMM-CMs
(18%, 6/34). The second type of arrhythmia recorded from hiPSC-
CMs was phase 3 early afterdepolarization (EAD). Phase 3 was
defined as the initiation of the next AP during the third phase of
repolarization, i.e. phase 3 in preceding APs (Fig. 2Ba; Fig. S1B).
EAD-induced triggered activity in hiPSC-CMs displayed take-off
potentials ranging between −55 mV and −65 mV. When the AP
comprising phase 3 EAD was closely analyzed, two distinctive
patterns of upstroke velocity were observed. Either the upstroke
velocity of AP constituting phase 3 EAD increased compared to its
previous AP, or it remained the same (Fig. 2Bb,c). In the baseline
condition, the percentage of cells exhibiting phase 3 EAD was
higher in both HCMT-CMs (20%, 52/263) and HCMM-CMs (13%,
21/158) than in WT-CMs (3%, 3/102) (Fig. 2Bd). Phase 3 EADs
were also recorded from the atrial hiPSC-CMs (Fig. S2B) fromWT-
CMs (5%, 1/21), HCMT-CMs (13%, 4/30) and HCMM-CMs (3%,
1/34). The third type of arrhythmia exhibited in hiPSC-CMs was
burst EAD. This type of EAD was defined as the sudden increase in
beating rate triggered by phase 3 EAD (Fig. 2Ca; Fig. S1C). The
main characteristics of burst EAD are a faster beat rate and
continuous change (either increasing or decreasing) in action
potential amplitude (APA). Similar to phase 3 EAD, another
notable characteristic observed in some of the burst was an increase
Fig. 2. Classification of arrhythmias recorded in ventricle-like hiPSC-CMs. (A)Representative AP recording with DADs (Aa), its first derivative (Ab), its phase
plot (Ac) and percentage of cells exhibiting DADs (Ad). (B) Representative AP recording with phase-3 EAD (Ba), its first derivative (Bb), its phase plot (Bc) and
percentage of cells exhibiting phase-3 EAD (Bd). (C) Representative AP recording with burst EAD (Ca), its first derivative (Cb), its phase plot (Cc) and its
occurrence, calculated as number of bursts/total number of cells (Cd). (D)Representative AP recording with QES-EAD (Da), its first derivative (Db), its phase plot
(Dc) and its occurrence, calculated as number of QES-EADs/total number of cells (Dd). (E) Representative AP recordingwith VT-EAD (Ea), its first derivative (Eb),
its phase plot (Ec) and percentage of cells exhibiting VT (Ed). Arrowheads indicate the corresponding arrhythmias in APs. Dashed line represents 0 mV. (Formore
detail, see Fig. S3.)
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in the upstroke velocity in AP comprising burst EAD (Fig. 2Cb,c).
The length and beat rate of the burst EAD observed in hiPSC-CMs
ranged from 0.3 s to 27 s and from 50 beats per minute (BPM) to
260 BPM, respectively. Similarly, the take-off potential for burst in
our study ranged from −70 mV to −30 mV. Furthermore, the
occurrence of burst was two times higher in HCMT-CMs (8%, 20/
263) than in HCMM-CMs (4%, 7/158) and WT-CMs (4%, 4/102)
in baseline conditions (Fig. 2Cd). Similarly, bursts were also
observed in atrial-like hiPSC-CMs (Fig. S2C) from HCMT-CMs
(3%, 1/30) and HCMM-CMs (3%, 1/34), but not in those fromWT-
CMs (0%, 0/21). The fourth type of arrhythmia recorded from
hiPSC-CMs was quasi-equilibrium state (QES) EAD (QES-EAD),
which was defined as a sudden decrease in APA leading to
temporary non-beating membrane potential or oscillation and self-
recovery to spontaneous APs (Fig. 2Da; Fig. S1D). As in phase 3
EAD and burst EAD, an increase in upstroke velocity in AP
comprising QES-EAD was observed in some cases (Fig. 2Db,c).
The take-off potential and duration of QES-EAD recorded in our
study varied from −55 mV to −6.5 mV and from 1.4 s to 22.3 s,
respectively. At baseline conditions, QES-EADs were observed at
low incidence in WT-CMs (1%, 1/102), HCMT-CMs (1%, 3/263)
and HCMM-CMs (1%, 2/158) (Fig. 2Dd). However, QES-EADs
were not observed in atrial-like hiPSC-CMs. The fifth type of
arrhythmia observed in hiPSC-CMs was ventricular tachycardia
(VT), which was defined as phase 3 EAD mediating triggered
activity followed by an increased beating rate (Fig. 2Ea; Fig. 3). The
main characteristics of VT-EAD were a steady APD and maximum
diastolic potential (MDP) during triggered activity. Our results
showed that the beat rate and MDP of VT ranged from 70 BPM to
254 BPM and from −69 mV to−45 mV, respectively. Furthermore,
another distinguished feature of VT was the possibility of
progressively extended triggered activity. Therefore, VTs were
subdivided by duration as non-sustained (NSVT, duration <30 s,
self-terminated; Fig. 3A), sustained (SVT, duration>30 s, self-
terminated; Fig. 3C) and non-recovered (NRVT, not recovered;
Fig. 3B). Unlike other types of EAD, an alternation in upstroke
velocity constituting VT was not observed. The first four types of
arrhythmia (DAD, phase 3 EAD, burst and QES-EAD) were
observed in WT-CMs, HCMT-CMs and HCMM-CMs.
Interestingly, VTs were only found in HCMT-CMs. To confirm
that VTs were exclusively present in HCMT-CMs, we decided to
include the clonal line of UTA.02912.HCMT with the TPM1-
Asp175Asn mutation called UTA.02913.HCMT (Table S2, Fig.
S3). In current clamp recording, we were also able to record VTs in
hiPSC-CMs derived from the UTA.02913.HCMT line and therefore
confirmed that VT was present in HCMT-CMs.
Baseline variabilities in hiPSC-CMs
Clinically, it is well known that heart rate variabilities and/or
ventricular repolarization variabilities differ between control
individuals and diseased patients, and are associated with
arrhythmias present in the patients (Counihan et al., 1993). In
addition, an earlier study showed that hiPSC-CMs exhibited beat
rate variability (Mandel et al., 2012). Thus, the beat rate variabilities
[standard deviation of instantaneous variability (SD1), standard
deviation of long-term variability (SD2), standard deviation of
differences between adjacent RR intervals (SDSD) and standard
deviation of all RR intervals (SDRR)] and repolarization
variabilities [beat-to-beat variability at 50% or 90% repolarization
(STV-APD50 or STV-APD90)] were measured to understand
whether these variabilities differ in WT-CMs, HCMT-CMs and
HCMM-CMs. Thus, recordings of hiPSC-CMs with ≥30
consecutive APs without the presence of any type of arrhythmia
were selected from WT-CMs (n=79), HCMT-CMs (n=174) and
HCMM-CMs (n=118). First, the three-dimensional plots among
SD1, beat rate and APD90, and STV-APD90, beat rate and APD90,
were plotted (Fig. S4). After that, correlation tests were performed
among beat rate, beat rate and repolarization variabilities, and
APDs. The results showed a negative correlation between beat rate
and beat rate variabilities in all groups, i.e. the higher the beat rate,
the lower the beat rate variability (Fig. S5A-F). By contrast, we
found a positive correlation between APDs and APD variability in
Fig. 3. Representative AP profile of VT
arrhythmias recorded in HCMT-CMs.
(A) AP with non-sustained ventricular
tachycardia (NSVT, duration <30 s)
(B) non-recovered ventricular tachycardia
(NRVT) and (C) sustained ventricular
tachycardia (SVT, >30 s). Dashed line
represents 0 mV.
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all groups, i.e. the longer the APD, the higher the STV (Fig. S5G-L).
On the other hand, the results of correlation tests between beat rate
variabilities and repolarization variabilities showed a positive
relationship between SD1 and APD90 in HCMT-CMs and
HCMM-CMs (P<0.05, Pearson’s correlation) but not in WT-CMs
(Fig. S6). Therefore, to minimize the effects of beat rate and APDs
in their respective variabilities to compare among groups,
variabilities data from CMs were again filtered. The newly
selected CMs had beat rates ranging from 30 BPM to 60 BPM,
and also APDs of 200-600 ms. Consequently, the mean beat rates
(WT-CMs 52.5±1.4 versus HCMT-CMs 52.1±1.0 versus HCMM-
CMs 55.8±1.3), APD50 (WT-CMs 282.1±8.3 versus HCMT-CMs
283.3±6.7 versus HCMM-CMs 278.9±8.9) and APD90
(WT-CMs 333.6±9.0 versus HCMT-CMs 334.9±7.4 versus
HCMM-CMs 328.2±9.6) were not significantly different among
the groups (ns, one-way ANOVA, post hoc Tukey test; WT-CMs
n=63, HCMT-CMs n=154 and HCMM-CMs n=119; Fig. S7).
Thus, we compared variabilities among groups. Fig. 4 shows the
variabilities parameters in WT-CMs, HCMT-CMs and HCMM-
CMs. All the beat rate variabilities parameters, such as SD1, SD2,
SDRR and SDSD, were significantly higher (P<0.05, one-way
ANOVA, post hoc Tukey test) in HCMT-CMs and HCMM-CMs
than inWT-CMs (Fig. 4A-F). These results imply that both HCMT-
CMs and HCMM-CMs exhibit higher degrees of beat variability
thanWT-CMs. However, STV-APD90 and STV-APD50 were only
significantly higher (P<0.05, one-way ANOVA, post hoc Tukey
test) in HCMT-CMs compared to WT-CMs (Fig. 4E,F). The CMs
exhibiting a higher degree of beat rate and repolarization
variabilities were more scattered in Poincaré plot (Fig. 4I and
Fig. 3L). In addition, beat rate variabilities and repolarization
variabilities of atrial-like hiPSC-CMs from WT-CMs (n=21),
HCMT-CMs (n=27) and HCMM-CMs (n=33) were measured,
but no significant differences (ns, one-way ANOVA, post hoc
Tukey test) in any parameters were found among groups (Table S3).
Adrenaline testing in hiPSC-CMs
Adrenaline levels increase during exercise (Warren et al., 1984), and
HCM patients and healthy individuals have similar plasma
adrenaline levels during rest and exercise conditions (Omodani
et al., 1998). However, HCM patients experience lethal arrhythmia
during or immediately after exercise (Gimeno et al., 2009). To
understand whether adrenaline causes any adverse effects, hiPSC-
CMs were exposed to different concentrations of adrenaline,
including 0.1 nM, 0.5 nM, 1 nM, 10 nM, 100 nM, 1 µM and
10 µM. The hiPSC-CMs were administrated only one concentration
at a time to avoid the possible effect of desensitization of the
receptor (Priori and Corr, 1990). The experimental protocol for the
adrenaline testing is shown in Fig. S8.
Effects on AP characteristics during the administration of adrenaline
The effects of adrenaline were calculated as the percentage change
compared to pre-adrenaline administration. Fig. 5 summarizes the
Fig. 4. Summary of variabilities in
hiPSC-CMs. (A-F) Comparison of SD1,
SD2, SDRR, SDSD, STV-APD50 and
STV-APD90 in WT-CMs (n=63), HCMT-
CMs (n=154) and HCMM-CMs (n=79).
Data are mean±s.e.m. *P<0.05,
**P<0.005 and ***P<0.0001; one-way
ANOVA, post hoc Tukey test).
(G-L) Representative AP traces (G,J),
with superimposed 30 APs (H,K) and
Poincaré plots of these APs from hiPSCs
exhibiting low (black circles) and high
(maroon circles) variabilities (I,L). Dashed
line represents 0 mV. (For more detail,
see Figs S6-S9.)
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effects of various concentrations of adrenaline on AP characteristics
in WT-CMs, HCMT-CMs and HCMM-CMs. The beat rates were
significantly increased (P<0.05, paired t-test), but APD50 and
APD90 were significantly decreased (P<0.05, paired t-test), from
their pre-adrenaline values in a concentration-dependent manner in
WT-CMs (Table S4), HCMT-CMs (Table S5) and HCMM-CMs
(Table S6) (Fig. 5A-C). Interestingly, APD50 and APD90 were
similarly reduced by adrenaline at all concentrations of adrenaline
(P<0.0001, APD50 versus APD90, Pearson’s correlation; data not
shown). Notably, upstroke velocity (dV/dt) was not significantly
changed by any concentration of adrenaline in WT-CMs, HCMT-
CMs and HCMM-CMs (P<0.05, paired t-test; Tables S4-S6). The
percentage changes in beat rate and APD90 were not always
dependent on their pre-adrenaline values or on one another, as
shown by correlation tests (Table S7).
Effects of adrenaline, during and immediately after administration, on
the occurrence of arrhythmias
To study the effects of adrenaline on arrhythmia frequencies, we
quantified those arrhythmias before exposure to adrenaline
(baseline condition), during the administration of adrenaline, and
immediately after washing off the adrenaline. Table S8 shows the
DAD rate in three different conditions in WT-CMs, HCMT-CMs
and HCMM-CMs. No significant differences in DAD rate when
comparing before, during and immediately after the wash-out
condition of different concentrations of adrenaline were observed in
WT-CMs, HCMT-CMs and HCMM-CMs (ns, Friedman, post hoc
Dunn test) at any concentration tested (Table S8). Similarly, phase 3
EAD rate at different concentrations were also quantified, but
significant changes were not observed at any concentration in any
group (ns, Friedman, post hoc Dunn test; Table S9). At higher
concentrations of adrenaline (>1 nM), bursts were not observed in
WT-CMs or HCMM-CM in the presence of adrenaline (Table S10).
However, bursts were recorded at all concentrations of adrenaline
tested both during administration and after washing out adrenaline
in HCMT-CMs (Table S10). Similarly, QES-EADs were observed
during the administration of adrenaline, except at the 100 nM
concentration in HCMT-CMs (Table S11). By contrast, QES-EADs
were observed in all three conditions at 100 nM adrenaline in WT-
CMs (Table S11). Furthermore, when studying the occurrence of
different types of VTs in HCMT-CMs, only NSVTs were observed
at baseline conditions. However, transition from NSVT to sustained
Fig. 5. Superimposed traces
representing the effects of different
concentrations of adrenaline on AP
characteristics. (A-F) Percentage
change in BPM (A), APD50 (B),
APD90, (C) MDP, (D) APA (E) and dV/
dt (F), with respect to pre-adrenaline
administration condition in WT-CMs,
HCMT-CMs and HCMM-CMs. One
concentration of adrenaline was tested
at a time. Data are mean±s.e.m.
*P<0.05, WT versus HCMT or HCMM;
#P<0.05, HCMT versus HCMM; one-
way ANOVA, post hoc Tukey test.
Table shows the number of cells used
in each group at different adrenaline
concentrations. (For more detail, see
Tables S4-S7.)
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SVT and/or NRVT was observed during the administration and
wash-out condition of adrenaline (Fig. 3; Table S12). NSVTs were
observed during the wash-out conditions from the 100 nM and
1 µM concentrations of adrenaline (Table S12).
Effects on variabilities during the administration of adrenaline
We also quantified the beat rate variabilities and repolarization
variabilities in hiPSC-CMs after the administration of adrenaline.
Similarly, as before, the percentage changes in variabilities were
calculated with respect to pre-adrenaline administration. Fig. 6A-D
and Fig. 6E,F summarize the changes in beat rate variabilities and
repolarization variabilities, respectively, with various concentrations
of adrenaline. Therewere nomajor significant differences in beat rate
variabilities in WT-CMs, HCMT-CMs and HCMM-CMs at any
adrenaline concentration (ns, one-way ANOVA, post hoc Tukey
test). Only the percentage changes in both repolarization variabilities
were significantly less at 1 nM and 10 nM of adrenaline in HCMT-
CMs when compared to HCMM-CMs or WT-CMs (*P<0.05, WT
versus HCMT at 10 nM adrenaline; #P<0.05, HCMT versus HCMM
at 1 nM adrenaline and 10 nM adrenaline; one-way ANOVA, post
hoc Tukey test; Fig. 6E,F). Although beat rates were increased and
APDs were decreased at increasing adrenaline concentrations, beat
rate and repolarization variabilities were not decreased in a similar
fashion in WT-CMs (Table S13), HCMT-CMs (Table S14) and
HCMM-CMs (Table S15).
Pharmacological treatment of HCM-specific hiPSC-CMs
Although there is currently no HCM-specific drug available, β-
blockers (class-II antiarrhythmic drug) are commonly prescribed to
HCM patients (Spoladore et al., 2012). In this study, bisoprolol was
used to investigate whether it would exert antiarrhythmic effects in
our hiPSC-CMs. Detailed information about the experimental
design for bisoprolol treatment is shown in Fig. S9. In brief,
extracellular solution with adrenaline was used prior to the
combination of adrenaline and bisoprolol, followed by solution
with bisoprolol alone.
Role of bisoprolol in HCMT-CMs
To examine the efficacy of β-blockers in HCMT-CMs, we chose to
administer 0.5 nM adrenaline because all types of arrhythmias were
observed at this concentration. At first, we evaluated the potency of
1 µM bisoprolol for 0.5 nM adrenaline in HCMT-CMs. DAD and
phase 3 EAD rates were not significantly (ns, Kruskal–Wallis, post
hoc Dunn test) reduced by bisoprolol in both the presence and wash-
out condition of 0.5 nM adrenaline (Fig. 7A,B,J,K). Bursts were
reduced by 1 µM bisoprolol in the presence of 0.5 nM adrenaline
(Fig. 7C) but not during the wash-out condition of 0.5 nM
adrenaline (Fig. 7L). In addition, 1 µM bisoprolol could not
reduce the occurrence of QES-EAD in the presence or in the wash-
out condition of 0.5 nM adrenaline (Fig. 7D,M). Next, the 10 µM
bisoprolol concentration was tested to determine whether a higher
Fig. 6. Superimposed traces representing the effects of different concentrations of adrenaline on beat rate and repolarization variabilities.
(A-F) Percentage change in SD1 (A), SD2 (B), SDRR (C), SDSD (D), STV-APD50 (E) and STV-APD90 (F) with respect to pre-adrenaline administration condition
in WT-CMs, HCMT-CMs and HCMM-CMs. Data are mean±s.e.m. *P<0.05, WT-CMs versus HCMT-CMs or HCMM-CMs; #P<0.05, HCMT-CMs versus
HCMM-CMs; one-way ANOVA, post hoc Tukey test. Table shows the number of cells used in each group at different adrenaline concentrations. (For more detail,
see Tables S13-15.)
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concentration of bisoprolol could reduce the arrhythmias. However,
10 µM bisoprolol could not decrease the DAD and phase 3 EAD
rates significantly (ns, Kruskal–Wallis, post hoc Dunn test), or
reduce the occurrence of burst and QES-EAD, in both the presence
and wash-out condition of 0.5 nM adrenaline (Fig. 7A-D,J-M). In
the presence of either 1 µM or 10 µM bisoprolol, VTs were
observed, indicating that bisoprolol failed to prevent the initiation
and termination of lethal arrhythmias in HCMT-CMs (Fig. 7E,N).
The role of bisoprolol in beat rate variabilities and repolarization
variabilities were studied, but no significant changes (ns, one-way
ANOVA, post hoc Tukey test) were found in the presence of 1 µM
or 10 µM bisoprolol (Fig. 7F-I).
Role of bisoprolol in HCMM-CMs
We also investigated the potency of both 1 µM and 10 µM
bisoprolol in the presence and wash-out conditions of 10 nM
adrenaline in HCMM-CMs. As shown above, the higher
concentrations of adrenaline decreased the occurrence of
arrhythmias in HCMM-CMs; thus, a lower concentration of
adrenaline was preferred, and the 10 nM adrenaline concentration
was chosen. As in HCMT-CMs, neither 1 µM nor 10 µM bisoprolol
reduced the DAD rate and phase 3 EAD rate significantly (ns,
Kruskal–Wallis, post hoc Dunn test) in the presence and wash-out
condition of 10 nM adrenaline (Fig. 8A,B,I,J). Burst was not
observed in the presence of 1 µM bisoprolol and 10 nM adrenaline
and during the wash-out condition of 10 nM adrenaline (Fig. 8C,K).
However, bursts were observed in the presence of 10 µM bisoprolol
and 10 nM adrenaline, but not during the wash-out condition of
10 nM adrenaline (Fig. 8C,K). Notably, QES-EADs were increased
by both 1 µM and 10 µM bisoprolol in the presence and wash-out
condition of 10 nM adrenaline (Fig. 8D,L). Furthermore, the beat
rate variabilities and repolarization variabilities were not
significantly changed (ns, one-way ANOVA, post hoc Tukey test)
by bisoprolol in HCMM-CMs (Fig. 8E-H).
DISCUSSION
In our previous study (Ojala et al., 2016), we demonstrated the
phenotypic characteristics of HCM in hiPSC-CMs, such as a
higher degree of arrhythmias and abnormal calcium handling at
baseline conditions. To our knowledge, this is the first study
investigating the electrophysiological properties of HCM-specific
hiPSC-CMs during the administration and immediately after the
wash-out conditions of various concentrations of adrenaline.
Furthermore, we investigated the potency of bisoprolol as an
antiarrhythmic drug in HCM-specific hiPSC-CMs. Our main
findings in the current study are as follows: (1) ICa and Ito are
remodeled in HCM-specific hiPSC-CMs; (2) frequencies of
ventricular arrhythmias are dependent on concentrations of
Fig. 7. Treatment of HCMT-CMs with bisoprolol. (A-E) Quantification of the occurrence of arrhythmia in the presence of 0.5 nM adrenaline (0.5 nM A),
with addition of 1 μM (0.5 nM A+1 μM B) and 10 μM (0.5 nM A+10 μM B) bisoprolol. (F-I) Summary of SD1, SD2, STV-APD50 and STV-APD90 in the
presence of 0.5 nM adrenaline with addition of 1 μM and 10 μM bisoprolol (n=14 for 0.5 nM A, n=4 for 0.5 nM A+1 μM B and n=7 for 0.5 nM A+10 μM B).
(J-N) Quantification of the occurrence of arrhythmia during the wash-out condition of 0.5 nM adrenaline with 0 μM (no B), 1 μM (1 μM B) and 10 μM (10 μM B)
bisoprolol (n=24 for 0.5 nM A/no B, n=9 for 0.5 nM A+1 μM B/1 μM B and n=15 for 0.5 nMA+10 μM B/10 μM B).
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adrenaline and position of mutation in genes causing HCM; (3) VT
types of arrhythmia are observed in HCMT-CMs, but not in
HCMM-CMs; and (4) bisoprolol cannot cure arrhythmias in
HCM-specific hiPSC-CMs.
Remodeling of ion channels and arrhythmias
The calcium current densities in both HCM-specific hiPSC-CMs
were higher than in WT-CMs, which might explain the
prolongation of APD90 in HCM-CMs as shown in our previous
study (Ojala et al., 2016). However, in our earlier study, APD90s of
HCMT-CMs were longer than those of HCMM-CMs, despite
similar ICa (Ojala et al., 2016). Although ICa is one of the main
components in determining the APD (Han et al., 2014), there are
other possible reasons for APD prolongation, such as increased late
sodium current (Coppini et al., 2013), decreased rapid-delayed
rectifier potassium current (Lahti et al., 2011) and reduced slow-
delayed rectifier potassium current (Ma et al., 2015). Interestingly,
decreased Ito current densities in our HCM-specific hiPSC-CMs
was similar to what was observed in isolated cells from HCM
patients (Coppini et al., 2013), but this was contradictory to hiPSC-
CMs from HCM patients in another study (Han et al., 2014).
Furthermore, we found contradictory results in IK1 current densities
from previous publications, in which isolated cells from HCM
patients were used (Coppini et al., 2013). The remodeling of ion
channels is considered one of the causes of arrhythmias in HCM
(Tomaselli and Marbán, 1999; Knollmann et al., 2003). The
characteristics of arrhythmias in HCM have been extensively
studied using different models, such as experimental (animal and
isolated CMs) (Coppini et al., 2013; Knollmann et al., 2003) and
computer models (Passini et al., 2016; Zile and Trayanova, 2017).
DAD and EAD could coexist and affect one another because of
bidirectional calcium-voltage coupling (Song et al., 2015). The
potential mechanisms of DAD (January and Fozzard, 1988), phase
3 EAD (Burashnikov and Antzelevitch, 2003), burst (Chang et al.,
2012), long plateau (Song et al., 2015) and VT (Maruyama et al.,
2011) types of arrhythmia were described in early studies.
Importantly, one distinguished feature observed from the first
derivative of all EADs was that the upstroke velocity of EADs was
much lower compared to that in APs comprising EAD [Fig. 2, first
derivative (Bb,Cb,Db) and phase plots (Bc,Cc,Dc)]. Additionally,
phase 3 EAD, burst and QES-EAD arrhythmias recorded during the
current clamp might correspond to the double peak, oscillation and
plateau types of calcium dynamics, respectively, shown in our
earlier study (Ojala et al., 2016). Taken together, these results
indicate that these arrhythmias are possibly calcium-driven
phenomena.
Fig. 8. Treatment of HCMM-CMs with bisoprolol. (A-D) Quantification of the occurrence of arrhythmia in the presence of 10 nM adrenaline (10 nM A), with
addition of 1 μM (10 nM A+1 μM B) and 10 μM (10 nM A+10 μM B) bisoprolol. (E-H) Summary of SD1, SD2, STV-APD50 and STV-APD90 following the
administration of 10 nMA, 10 nMA+1 μMB and 10 nMA+10 μMB (n=12 for 10 nMA; n=17 for 10 nM A+1 μMB; and n=12 for 10 μMB). (I-L) Quantification of the
occurrence of arrhythmias during wash-out condition of 10 nM Awith 0 μM (no B), 1 μM (1 μMB) and 10 μM (10 μMB) bisoprolol (n=18 for 10 nM A/no B, n=25 for
10 nM A+1 μM B/1 μM B and n=15 for 10 nM A+10 μM B/10 μM B).
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Variabilities in hiPSC-CMs
Clinically, the heart rate variabilities in HCM gave mixed results as
those parameters depend on age of patients and thickness of left
ventricular mass (Counihan et al., 1993; Alter et al., 2006). The
variabilities of repolarization indicate a repolarization reserve,
suggesting that the higher the variability, the larger the
susceptibility for repolarization-dependent ventricular arrhythmias
(Varró and Baczkó, 2011). In an early clinical study, the short-term
variability (STV) of QT interval was significantly higher in HCM
patients than in healthy individuals (Orosz et al., 2015). Another
study found that CMs exhibiting ventricular fibrillation (VF) have
increased variabilities in APD50 and APD90 than CMs not
displaying VF (Sridhar et al., 2008). In our results, VT
arrhythmias were only seen in HCMT-CMs, which display
significantly higher repolarization variability than WT-CMs.
Thus, this indicates the link between repolarization variabilities
and VT types of arrhythmias.
Role of adrenaline in the occurrence of arrhythmias
Most previous studies have focused on isoproterenol for β-adrenergic
stimulation and shown an increased amount of arrhythmias in HCM
models (Lan et al., 2013; Han et al., 2014; Knollmann et al., 2003).
However, we used adrenaline over isoproterenol for β-adrenergic
stimulation in this study because adrenaline is an endogenous
catecholamine,whereas isoproterenol is an exogenous agent, i.e. not a
natural compound. Although isoproterenol only activates the β- (both
β1 and β2) adrenergic pathway, adrenaline stimulates both α- and β-
adrenergic receptors (Brodde and Michel, 1999). In human, the
physiological plasma adrenaline concentration during rest is
∼0.12 nM/l (Omodani et al., 1998; Warren et al., 1984), and
adrenaline causes a positive inotropic effect and a decrease inAPD90,
mainly via the β-adrenergic pathway (Jakob et al., 1988). In contrast to
these results, our previous work on catecholaminergic polymorphic
ventricular tachycardia (CPVT) using hiPSC-CMs showed that
administration of adrenaline (1 µM) increased the arrhythmic
episodes in CPVT-specific hiPSC-CMs (Kujala et al., 2012;
Penttinen et al., 2015). These conflicting results demonstrate that
the different gene mutations inside cardiomyocytes (CMs) give
distinct responses, even though the adrenaline levels are the same.
Although the TPM1-Asp175Asn mutation causing HCM has been
considered benign or to represent intermediary risk (Coviello et al.,
1997), Hedman and co-workers suggested that HCM patients
carrying TPM1-Asp175Asn mutation were at increased risk of fatal
arrhythmias, and a number of these patients had SCD at a young or
middle age, or presented two or three clinical markers for increased
risk of SCD [family history of SCD, syncope, NSVT, pathological
blood pressure response, marked (>2.5 cm) hypertrophy] (Hedman
et al., 2004). On the other hand, the MYBPC3-Gln1061X mutation
exhibited age-related penetrance with delayed onset of the disease
(Jääskeläinen et al., 2002). Moreover, NSVTs were observed in a
higher number of HCM patients carrying MYBPC3-Gln1061X
mutations than HCM patients carrying the TPM1-Asp175Asn
mutation (23% versus 10%) during 24-h electrocardiogram
monitoring (Jääskeläinen et al., 2013). However, in our hiPSC-CM
study,we onlyobservedVT types of arrhythmia inHCMT-CMs, thus
our finding is in line with earlier clinical studies of patients with the
TPM1-Asp175Asnmutation being at increased risk of arrhythmia. In
previous clinical exercise tests, some HCM patients experienced
NSVT and VF, and all were asymptomatic (Gimeno et al., 2009). In
our study, HCM patients whose hiPSC-CMs showed NSVT are also
clinically asymptomatic; however, the NSVT transition to SVT or
NRVT occurred only after the administration of adrenaline. Xie et al.
(2014) presented a possible mechanism of this transition via
β-adrenergic stimulation. Although the occurrence of arrhythmias
during exercise is infrequent in HCM, existence of such arrhythmias
can be linked to increased risk of SCD (Gimeno et al., 2009). Patel
et al. (2014) found that the peak heart rate during exercise testing was
lower in HCM patients than in controls. The possible reason for
slower heart rate might be reduction in β-adrenergic receptor density
(Choudhury et al., 1996) and a desensitized cardiac β-adrenergic
system under normal plasma catecholamines in HCM (Schumacher
et al., 1995).
Pharmacology in HCM-specific hiPSC-CMs
Bisoprolol is a selective β1-adrenoceptor blocker (Brixius et al., 2001)
and has been used to improve exercise capacity in heart failure (Issa
et al., 2007; Dubach et al., 2002). In another clinical study on heart
failure, bisoprolol reduced heart rate and increased the heart rate
variability parameter (Pousset et al., 1996). Contradictory to our
results, earlier studies claimed that β-blockers were able to reduce
arrhythmias in HCM-specific hiPSC-CMs (Lan et al., 2013; Han
et al., 2014). The possible reasons for these conflicting results might
be differences in the study design, including long-term administration
versus short-term administration, different concentration and different
types of β-adrenergic agonist/antagonist used in our study.
Furthermore, we specifically categorized the arrhythmias presented
in our hiPSC-CMs, which had not been done in earlier studies (Han
et al., 2014; Lan et al., 2013). In addition, an early study comparing
antiarrhythmic drug therapyand ICD showed that ICDwas superior to
antiarrhythmic drugs among patients who experienced VF or
sustained VT [Antiarrhythmics versus Implantable Defibrillators
(AVID) Investigators, 1997]. The previous study showed that
programmed ventricular stimulations (PVS) induced SVT or VF in
33% (7/21) of HCM patients carrying the TPM1-Asp175Asn
mutation, although 57% (4/7) of those vulnerable HCM patients
were under β-blocker therapy (Hedman et al., 2004), indicating that β-
blocker treatment is suboptimal in arrhythmia prevention in HCM.
Taken together, these results indicate that ICD therapy is the only
proven technique for effective termination of VT episode, preventing
SCD in high-risk HCM patients (Trivedi and Knight, 2016).
Study limitations
Although our comprehensive study revealed previously unknown
roles of adrenaline and bisoprolol in HCM-specific hiPSC-CMs, it
also raises some new questions. Why do hiPSC-CMs with different
HCM-causing mutations respond differently to endogenous
adrenaline and why are VT types of arrhythmia exclusively
presented in hiPSC-CMs with mutation in TPM1-Asp175Asn?
However, it is beyond the scope of this study to suggest a promising
mechanism of the arrhythmias in these hiPSC-CMs. In addition,
owing to their developmental immaturity, these hiPSC-CMs exhibit
some essential differences from adult CMs, such as lack of t-tubules
and low-level expression of IK1 (KCNJ2). Thus, these hiPSC-CMs
do not fully resemble adult CMs. Furthermore, hiPSC-CMs do not
recapitulate the tissue-level disease phenotype, including interstitial
fibrosis and myocardial disarray. Moreover, the human heart
develops under the continuous presence of catecholamine in
blood and neurointervention, which is certainly not similar in the
case of in vitro maturation of hiPSC-CMs. Furthermore, the human
heart mainly consists of myocytes with other cell types, such as
endothelial cells and fibroblasts, and involves crosstalk between the
cells. However, hiPSC-CMs lack other cell types and cell-cell
communication; thus, microscopic single hiPSC-CMs cannot
completely model the whole macroscopic human heart. Moreover,
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the mutations associated with HCM patients studied herein are the
most common mutations in Finland. Therefore, these results might
only be specific to these mutations and cannot readily be
extrapolated to all HCM patients. Generating the isogenic control
cell lines by correcting the HCM-causing mutation with the help of
CRISPR/Cas9 to understand the mechanism of HCM diseases in a
better way is the aim of future studies.
Conclusions
This study has clearly shown that while studying β-adrenergic
stimulation and blockage in HCM, it is extremely important to
address not only during the administration of agonists/antagonist,
but also immediately after washing out. Furthermore, the hiPSC-
CM model provides a safe and robust platform to study the genetic
cardiac diseases. We strongly believe that our results contribute to a
better understanding of HCM and create a foundation for future
investigation.
MATERIALS AND METHODS
Ethical approval
BioMediTech (Heart Group) has received permission from the Ethics
Committee of Pirkanmaa Hospital District to conduct research in hiPSCs
(R08070). Skin biopsies for hiPSC establishment were received from the
Heart Hospital, Tampere University Hospital, Tampere, Finland. The
patients donating skin biopsies provided written informed consent.
Patient-specific hiPSC lines and hiPSC-derived CMs
Seven hiPSC lines were used in this study: three lines with mutation in
TPM1 (TPM1-Asp175Asn) (UTA.13602.HCMT, UTA.02912.HCMT and
UTA02913.HCMT), two lines with mutation in MYBPC3 (MYBPC3-
Gln1061X): (UTA.06108.HCMM and UTA.07801.HCMM), and two lines
derived fromhealthy individuals (UTA.04602.WTandUTA.04511.WT). The
characterization of all other hiPSC lines except UTA.02913.HCMT was
performed inour previous study (Ojala et al., 2016).Details onhiPSC lines and
individuals from whom hiPSC lines were derived are presented in Table S2.
The characterization of UTA.02913.HCMT is shown in Fig. S3. hiPSCs were
differentiated into CMs (hiPSC-CMs) by co-culturing with mouse visceral
endoderm-like cells (END-2) as described in our previous study (Ojala et al.,
2016). In this study, 40- to 85-day-old hiPSC-CMswere used for experiments,
and control cell lines and cell lines with each mutation were combined in
groups. Two hiPSC-CMs derived from two healthy individuals without any
known mutations causing HCM were combined to make the WT-CM group.
Furthermore, three hiPSC-CMs from two different individuals carrying the
same TPM1 (TPM1-Asp175Asn) mutation were combined to make the
HCMT-CM group. Similarly, two hiPSC-CMs from two different individuals
carrying the same MYBPC3 (MYBPC3-Gln1061X) mutation were combined
to make the HCMM-CM group.
Chemicals and drugs
All drugs and chemicals for electrophysiology experiments were purchased
from Sigma-Aldrich (USA) unless otherwise specified. Potassium
methanesulfonate (KMeSO4) was ordered from MP Biomedicals (USA).
(±)-Epinephrine hydrochloride (adrenaline) was dissolved in Milli-Q water,
tightly sealed in an Eppendorf tube and stored at −20°C. Cadmium chloride
(CdCl2) and barium chloride (BaCl2) were dissolved in Milli-Q water and
stored at 4°C. On the day of experiments, the drugs were diluted to the final
concentration in extracellular solution. 4-Aminopyridine (4-AP) was
dissolved in the extracellular solution on the day of experiment.
Amphotericin-B was first dissolved in dimethyl sulfoxide (DMSO,
Sigma-Aldrich) and then added to intracellular solution to a final
concentration of 0.24 mg/ml and stored at 4°C during experiments.
Current clamp
APs were recorded in the gap-free mode from hiPSC-CMs using a
perforated patch configuration with amphotericin B as previously described
(Ojala et al., 2016). In brief, the hiPSC-CMs were continuously perfused at
36±1°C with an extracellular solution containing 143 mM NaCl, 4.8 mM
KCl, 1.8 mM CaCl2, 1.2 mM MgCl2, 5 mM glucose and 10 mM HEPES
(pH was adjusted to 7.4 with NaOH). The intracellular solution contained
132 mM KMeSO4, 20 mM KCl, 1 mM MgCl2, 4 mM EGTA and 1 mM
CaCl2 (pH was adjusted to 7.2 with KOH).
Voltage clamp
Once the stable baseline APs were obtained, the amplifier was switched into
voltage clamp mode to record ionic currents maintaining the same
extracellular solution. Ionic currents were divided by cell capacitances and
presented as pA/pF. All measurements were performed at 36±1°C. The
calcium current (ICa) was measured with a depolarizing potential of −50 mV
to 80 mVwith 10 mV increments. The holding potential (HP)was−40 mV to
inactivate the sodium channels, and 3 mM 4-AP was used in the extracellular
solution to block the transient outward potassium current (Ito). Early study
showed that there was less contamination from sodium ions in the calcium
current measurement (Fatima et al., 2013), Ito was sodium dependent, and
either removing or blocking sodium ions reduced the peak Ito current (Dukes
andMorad, 1991). Thus, sodium ionswere not removed and sodium channels
were not blocked in this study. Next, Ito was measured with the two-step
protocol from a HP of −80 mV: a first step of −50 mVwas used to inactivate
the sodium channels and then to test potentials from−50 mV to 70 mVwith a
step size of 10 mV. We added 300 µM CdCl2 to the extracellular solution to
block the calcium currents. The inward rectifier potassium current (IK1) was
measured with 2 mM BaCl2-sensitive current in the presence of 300 µM
CdCl2 and 3 mM 4-AP. The currents were elicited by a depolarizing potential
of −140 mV to 0 mV with 10 mV increments, and HP was −40 mV. In
addition, the IK1 current was extracted by the subtraction of currents recorded
with and without the presence of BaCl2 in the extracellular solution.
Variability analysis
Beat rate variability (BRV) was assessed from ≥30 consecutive APs
without the presence of arrhythmias. SD1 is the standard deviation (SD)
of the instantaneous (STV) beat-to-beat interval variability. SD2 is
the SD of the long-term interval variability (LTV). SD1 and SD2
were calculated using the formulae SD12=1/2×SDSD2 and
SD22=2SDRR2−1/2×SDSD2, respectively, in which SDRR represents
the SD of all RR intervals and SDSD represents the SD of differences
between adjacent RR intervals. Similarly, the STV-APD50 and STV-
APD90 were assessed in the same APs selected for BRV using
the formulae STV-APD50 ¼P jAPD50nþ1  APD50nj=½n
ﬃﬃﬃ
2
p  and
STV-APD90 ¼P jAPD90nþ1  APD90nj=½n
ﬃﬃﬃ
2
p , respectively. n
represents the number of APs used to calculate variabilities.
Data analysis
Recorded APs were analyzed using custom-made software in Origin9.1
(OriginLab Corp., USA) to extract BPM, APD50 and APD90, APA, dV/dt
and MDP. The recorded ionic currents were analyzed using Clampfit 10.7
(Molecular Devices, USA). The SD1, SD2, SDRR, SDSD, STV-APD50
and STV-APD90 were calculated using custom-made software in Matlab
R2015a (MathWorks, Inc., USA).
Statistical analysis
For independent group comparisons, a one-way ANOVA followed by
Tukey’s post hoc test was used for normally distributed data. In addition, a
paired t-test was used for the dependent normally distributed data. For
the three independent variables, the Kruskal–Wallis test followed by the
Dunn test was used for non-normally distributed data. For the three
dependent variables, the Friedman test followed by the Dunn test was used
for non-normally distributed data. A two-tailed P<0.05 was considered
statistically significant. Data are presented as mean±standard error of mean
(s.e.m.).
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Supplementary information
Supplementary information available online at
http://dmm.biologists.org/lookup/doi/10.1242/dmm.032896.supplemental
References
Adabag, A. S., Casey, S. A., Kuskowski, M. A., Zenovich, A. G. and Maron, B. J.
(2005). Spectrum and prognostic significance of arrhythmias on ambulatory
Holter electrocardiogram in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 45,
697-704.
Alter, P., Grimm, W., Vollrath, A., Czerny, F. and Maisch, B. (2006). Heart rate
variability in patients with cardiac hypertrophy—Relation to left ventricular mass
and etiology. Am. Heart J. 151, 829-836.
Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997).
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in
patients resuscitated from near-fatal ventricular arrhythmias.N. Engl. J. Med. 337,
1576-1584.
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